FDMT 4D MOLECULAR THERAPEUTICS IN revenue, earnings and financials
For the quarter ended June 30, 2026, 4D MOLECULAR THERAPEUTICS IN reported revenue of $3.78M (up 25106.7% from a year earlier), net income of −$72.9M and diluted EPS of −$1.04; over the last four quarters revenue was $92.0M and net income −$179M; for the fiscal year ended December 2025 revenue was $85.2M, up 230194.6% on the year before.
FDMT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $85.2M, gross profit n/a, operating income −$160M, net income −$140M (margin -164.4%), EPS −$2.42
- Fiscal year ended Dec 2024: revenue $37.0K, gross profit n/a, operating income −$188M, net income −$161M (margin -434778.4%), EPS −$2.98
- Fiscal year ended Dec 2023: revenue $20.7M, gross profit n/a, operating income −$113M, net income −$101M (margin -486.6%), EPS −$2.58
- Fiscal year ended Dec 2022: revenue $3.13M, gross profit n/a, operating income −$110M, net income −$107M (margin -3435.4%), EPS −$3.32
- Fiscal year ended Dec 2021: revenue $18.0M, gross profit n/a, operating income −$71.3M, net income −$71.3M (margin -395.4%), EPS −$2.57
FDMT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $3.78M (up 25106.7% year over year), net income −$72.9M, EPS −$1.04
- Quarter ended Mar 31, 2026: revenue $3.05M (up 21664.3% year over year), net income −$68.8M, EPS −$1.01
- Quarter ended Dec 31, 2025 (from the annual report): revenue $85.1M (up 8508900.0% year over year), net income $19.4M, EPS $0.43
- Quarter ended Sep 30, 2025: revenue $90.0K (up 2900.0% year over year), net income −$56.9M, EPS −$1.01
- Quarter ended Jun 30, 2025: revenue $15.0K (up 200.0% year over year), net income −$54.7M, EPS −$0.98
- Quarter ended Mar 31, 2025: revenue $14.0K (down 50.0% year over year), net income −$48.0M, EPS −$0.86
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.00K (up 105.6% year over year), net income −$49.7M, EPS −$0.90
- Quarter ended Sep 30, 2024: revenue $3.00K (down 100.0% year over year), net income −$43.8M, EPS −$0.79
- Quarter ended Jun 30, 2024: revenue $5.00K (down 97.9% year over year), net income −$35.0M, EPS −$0.63
- Quarter ended Mar 31, 2024: revenue $28.0K (down 90.6% year over year), net income −$32.4M, EPS −$0.66
- Quarter ended Dec 31, 2023 (from the annual report): revenue −$18.0K (down 101.4% year over year), net income −$32.3M, EPS −$0.69
- Quarter ended Sep 30, 2023: revenue $20.2M (up 3940.8% year over year), net income −$10.3M, EPS −$0.24
- Quarter ended Jun 30, 2023: revenue $239K (up 47.5% year over year), net income −$29.6M, EPS −$0.77
- Quarter ended Mar 31, 2023: revenue $298K (down 75.6% year over year), net income −$28.7M, EPS −$0.88
- Quarter ended Dec 31, 2022 (from the annual report): revenue $1.25M (up 1256.5% year over year), net income −$27.4M, EPS −$0.84
- Quarter ended Sep 30, 2022: revenue $500K (down 63.4% year over year), net income −$25.7M, EPS −$0.79
- Quarter ended Jun 30, 2022: revenue $162K (down 98.9% year over year), net income −$28.1M, EPS −$0.87
- Quarter ended Mar 31, 2022: revenue $1.22M (down 39.1% year over year), net income −$26.3M, EPS −$0.82
- Quarter ended Dec 31, 2021 (from the annual report): revenue $92.0K, net income −$25.1M, EPS −$0.86
- Quarter ended Sep 30, 2021: revenue $1.37M, net income −$22.2M, EPS −$0.82
FDMT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$109M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$135M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$75.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$86.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$69.1M, share buybacks n/a
FDMT balance sheet
- Jun 30, 2026: cash $70.4M, total assets $493M, total liabilities $85.0M, shareholders' equity $408M, long-term debt $19.6M
- Mar 31, 2026: cash $72.5M, total assets $513M, total liabilities $61.1M, shareholders' equity $452M
- Dec 31, 2025: cash $60.2M, total assets $567M, total liabilities $61.0M, shareholders' equity $506M, long-term debt $0
- Sep 30, 2025: cash $48.6M, total assets $424M, total liabilities $55.0M, shareholders' equity $369M
- Jun 30, 2025: cash $77.2M, total assets $474M, total liabilities $52.7M, shareholders' equity $421M
- Mar 31, 2025: cash $134M, total assets $516M, total liabilities $46.0M, shareholders' equity $470M
- Dec 31, 2024: cash $149M, total assets $560M, total liabilities $49.8M, shareholders' equity $511M
- Sep 30, 2024: cash $188M, total assets $604M, total liabilities $51.1M, shareholders' equity $553M
What is FDMT's revenue?
4D MOLECULAR THERAPEUTICS IN reported $92.0M of revenue over its last four quarters, through June 30, 2026.
Is FDMT profitable?
No. 4D MOLECULAR THERAPEUTICS IN lost $179M over the last four quarters.
What is FDMT's EPS?
Diluted earnings per share over the last four quarters were −$2.63; −$1.04 in the latest quarter.